Reading Time: 2 minutesIntroduction Testosterone replacement therapy (TRT) has been a subject of considerable debate, particularly regarding its safety in men with pre-existing cardiovascular disease (CVD). Fortesta, a topical testosterone gel, has been increasingly utilized for managing hypogonadism in this demographic. This article presents a comprehensive retrospective study spanning a decade to assess the safety of Fortesta in American males with CVD, providing crucial insights into its long-term effects. Study Design and Methodology The retrospective study analyzed data from over 1,000 American males diagnosed with both hypogonadism and CVD, who were prescribed Fortesta over a 10-year period. The primary endpoints were cardiovascular events, … Continue reading
-
Injectable Sermorelin
-
Search -
Archives
- May 2025
- April 2025
- March 2025
- February 2025
- April 2024
- March 2024
- December 2023
- November 2023
- October 2023
- September 2023
- August 2023
- July 2023
- June 2023
- May 2023
- April 2023
- March 2023
- February 2023
- January 2023
- December 2022
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- December 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- February 2019
- January 2019
-
HGH Decline Charts
-
Sermorelin Products
-
Sermorelin Health